Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine randomisierte, doppelblinde, placebokontrollierte Phase-IIB-Studie von Elismetrep (K-304) bei der Behandlung von Migräne

30. Oktober 2026 aktualisiert von: TriGemX Bio, Inc.

Eine randomisierte, doppelblinde, placebokontrollierte Phase-IIB-Studie von Elismetrep (K-304) bei der Behandlung von Migräne: Eine Reihe von Dosen wird bewertet

This is a double-blind, randomized, multicenter, outpatient evaluation of the safety and efficacy of elismetrep as compared to placebo in the acute treatment of migraine.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

431

Phase

  • Phase 2

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Alabama
      • Birmingham, Alabama, Vereinigte Staaten, 35205
        • Central Research Associates, LLC (CRA) dba Flourish Research
      • Mobile, Alabama, Vereinigte Staaten, 36608
        • AMR Mobile
    • Arizona
      • Tucson, Arizona, Vereinigte Staaten, 85710
        • Wake Research/ Tucson Neuroscience Research
    • California
      • Canoga Park, California, Vereinigte Staaten, 91303
        • Hope Clinical Research
      • Encino, California, Vereinigte Staaten, 91316
        • WR-PRI, LLC (Encino)
      • Huntington Beach, California, Vereinigte Staaten, 92647
        • Marvel Clinical Research
      • La Mesa, California, Vereinigte Staaten, 91942
        • Eximia Research - CA
      • Lemon Grove, California, Vereinigte Staaten, 91945
        • Synergy San Diego
      • Newport Beach, California, Vereinigte Staaten, 92660
        • WR-PRI, LLC (Newport Beach)
      • Oceanside, California, Vereinigte Staaten, 92056
        • Excell Research, Inc.
      • Pomona, California, Vereinigte Staaten, 91767
        • Empire Clinical Research
      • Riverside, California, Vereinigte Staaten, 92503
        • Artemis Institute for Clinical Research - Riverside
      • San Diego, California, Vereinigte Staaten, 89109
        • Acclaim Clinical Research
      • San Diego, California, Vereinigte Staaten, 92103
        • Artemis Institute for Clinical Research - San Diego
      • Walnut Creek, California, Vereinigte Staaten, 94598
        • Diablo Clinical Research, Inc.
      • West Hills, California, Vereinigte Staaten, 91307
        • Focus Clinical Research
    • Connecticut
      • Cromwell, Connecticut, Vereinigte Staaten, 06416
        • CT Clinical Research
    • Georgia
      • Atlanta, Georgia, Vereinigte Staaten, 30329
        • DelRicht Research
      • Stockbridge, Georgia, Vereinigte Staaten, 30281
        • Clinical Research Atlanta - Stockbridge
    • Idaho
      • Boise, Idaho, Vereinigte Staaten, 83704
        • Northwest Clinical Trials
    • Illinois
      • Chicago, Illinois, Vereinigte Staaten, 60607
        • Cedar Crosse Research Center
      • Flossmoor, Illinois, Vereinigte Staaten, 60422
        • Healthcare Research Network II, LLC
    • Kansas
      • Overland Park, Kansas, Vereinigte Staaten, 66202
        • Collective Medical Research
      • Wichita, Kansas, Vereinigte Staaten, 67207
        • Alliance for Multispecialty Research
    • Kentucky
      • Louisville, Kentucky, Vereinigte Staaten, 40213
        • L-MARC Research Center
    • Louisiana
      • Chalmette, Louisiana, Vereinigte Staaten, 70043
        • Crescent City Headache & Neurology Center
      • New Orleans, Louisiana, Vereinigte Staaten, 70115
        • DelRicht Research
    • Michigan
      • Ann Arbor, Michigan, Vereinigte Staaten, 48104
        • Michigan Head Pain and Neurological Institute
    • Minnesota
      • Minneapolis, Minnesota, Vereinigte Staaten, 55402
        • Clinical Research Institute
    • Mississippi
      • Gulfport, Mississippi, Vereinigte Staaten, 39503
        • DelRicht Research
    • Missouri
      • Hazelwood, Missouri, Vereinigte Staaten, 63042
        • Healthcare Research Network
    • Nevada
      • Las Vegas, Nevada, Vereinigte Staaten, 89109
        • Excel Clinical Research
      • North Las Vegas, Nevada, Vereinigte Staaten, 89119
        • Las Vegas Clinical Trials
    • New Mexico
      • Albuquerque, New Mexico, Vereinigte Staaten, 87102
        • Albuquerque Clinical Trials, Inc.
    • New York
      • Amherst, New York, Vereinigte Staaten, 14226
        • Dent Neurosciences Research Center
      • Manlius, New York, Vereinigte Staaten, 13104
        • CNY Clinical Research
      • Rochester, New York, Vereinigte Staaten, 14609
        • Rochester Clinical Research
      • Williamsville, New York, Vereinigte Staaten, 14221
        • Upstate Clinical Research Associates LLC
    • North Carolina
      • Greensboro, North Carolina, Vereinigte Staaten, 27405
        • Headache Wellness Center
      • High Point, North Carolina, Vereinigte Staaten, 27260
        • Peters Medical Research
    • Ohio
      • Cincinnati, Ohio, Vereinigte Staaten, 45212
        • CTI Clinical Research Center
    • Oklahoma
      • Edmond, Oklahoma, Vereinigte Staaten, 73034
        • OK Clinical Research, LLC
      • Oklahoma City, Oklahoma, Vereinigte Staaten, 73102
        • Hightower Clinical
      • Tulsa, Oklahoma, Vereinigte Staaten, 74133
        • DelRicht Research
      • Yukon, Oklahoma, Vereinigte Staaten, 73099
        • Tekton Research
    • Oregon
      • Portland, Oregon, Vereinigte Staaten, 97210
        • Summit Research Network
    • Pennsylvania
      • Allentown, Pennsylvania, Vereinigte Staaten, 18103
        • Lehigh Center for Clinical Research
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19114
        • Clinical Research Philadelphia, LLC
      • Scottdale, Pennsylvania, Vereinigte Staaten, 15683
        • Frontier Clinical Research, LLC
      • Smithfield, Pennsylvania, Vereinigte Staaten, 15478
        • Frontier Clinical Research, LLC
      • West Chester, Pennsylvania, Vereinigte Staaten, 19380
        • Atlas-Clinical
    • South Carolina
      • Charleston, South Carolina, Vereinigte Staaten, 29406
        • Clinical Trials of South Carolina
      • North Charleston, South Carolina, Vereinigte Staaten, 29405
        • Coastal Carolina Research Center
    • Tennessee
      • Chattanooga, Tennessee, Vereinigte Staaten, 37421
        • WR-ClinSearch
      • Knoxville, Tennessee, Vereinigte Staaten, 37909
        • AMR Knoxville (Formerly NOCCR)
      • Nashville, Tennessee, Vereinigte Staaten, 37203
        • Clinical Research Associates, Inc.
    • Texas
      • Austin, Texas, Vereinigte Staaten, 78745
        • Tekton Research
      • Austin, Texas, Vereinigte Staaten, 78737
        • Donald J Garcia Jr, MD, PA
      • Dallas, Texas, Vereinigte Staaten, 75251
        • FutureSearch Trials of Dallas, LP
      • Houston, Texas, Vereinigte Staaten, 77024
        • Victorium Clinical Research LTD CO
      • Splendora, Texas, Vereinigte Staaten, 77372
        • APD Clinical Research
      • Waxahachie, Texas, Vereinigte Staaten, 75165
        • ClinPoint Trials
    • Utah
      • Ogden, Utah, Vereinigte Staaten, 84405
        • Advanced Research Institute
    • Virginia
      • Newport News, Virginia, Vereinigte Staaten, 23606
        • Health Research of Hampton Roads, Inc.
    • West Virginia
      • Morgantown, West Virginia, Vereinigte Staaten, 26505
        • Frontier Clinical Research, LLC
    • Wisconsin
      • Kenosha, Wisconsin, Vereinigte Staaten, 53144
        • Clinical Investigation Specialist

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 70 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Be a male or female, age 18 to 70 years, inclusive, at the time of signing informed consent.

  2. Participant has greater than a one-year history of migraine with or without aura as defined by International Conference on Harmonization (IHS) criteria 1.1 and 1.2 and his/her migraines typically last between 4 to 72 hours, if untreated as documented in the participant's medical records from his/her treating physician and confirmed by the investigator.

  3. Participant has had ≥2 and ≤10 moderate or severe migraine attacks per month in each of the two months prior to screening (Visit 1).

  4. Meet the following requirements:

    1. Is a male OR

    2. Is a female who is of non-childbearing potential defined by at least 1 of the following criteria:

    3. Postmenopausal (aged >45 years and with a minimum of 12 months of spontaneous amenorrhea with a screening serum follicle-stimulating hormone (FSH) level in the menopausal range established for the central laboratory.

    4. Post hysterectomy, bilateral oophorectomy or bilateral salpingectomy, based on the participant's recall of their medical history.

      OR

    5. Is a female of reproductive potential and:

    6. agrees to remain abstinent from heterosexual activity*

      *Abstinence can be used as the sole method of contraception if it is in line with the participant's preferred and usual lifestyle and if considered acceptable by local regulatory agencies and ethics committees. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, post-ovulation methods, etc.) and withdrawal are not acceptable methods of contraception.

    7. or agrees to use (or have their partner use) a birth control method that is acceptable from the first dose of study drug until the end of trial (EoT) visit. Acceptable methods of birth control are:

      • combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation:

        • oral
        • intravaginal
        • transdermal
      • progestogen-only hormonal contraception associated with inhibition of ovulation:

        • oral
        • injectable
        • implantable
      • intrauterine device (IUD)

      • intrauterine hormone-releasing system (IUS)

      • bilateral tubal occlusion

      • vasectomised partner

      • sexual abstinence

      • progestogen-only oral hormonal contraception, where inhibition of ovulation is not the primary mode of action

      • male or female condom with or without spermicide

      • cap, diaphragm or sponge with spermicide

      • A combination of male condom with either cap, diaphragm or sponge with spermicide (double barrier methods)

    This condition is waived if the participant is proven to have no child-bearing potential (eg, hysterectomy).

  5. Participant voluntarily agrees to participate in the study by giving written informed consent.

  6. Participant is able to read, understand and complete the study questionnaires and diary.

  7. Be willing and able to comply with the study schedule of visits, all trial procedures and restrictions.

  8. Be willing to use their own personal, qualified smartphone to download study specific eDiary applications for use during the study.

Exclusion Criteria:

  1. Is a female who is pregnant, breast-feeding or intends to become pregnant during the planned course of the study. Note: Participants must have a negative serum pregnancy test (β-human chorionic gonadotropin (β-hCG)) performed by the central laboratory prior to enrollment in the study and negative urine pregnancy result at the randomization visit.

    Migraine history related

  2. Participant has difficulty distinguishing his/her migraine attacks from tension-type headaches.

  3. Participant has a history of predominantly mild migraine attacks or migraines that usually resolve spontaneously in less than two hours.

  4. Participant has more than 15 headache-days per month or has taken medication for acute headache on more than 10 days per month in any of the three months prior to screening (Visit 1).

  5. Participant has brainstem (a.k.a. basilar-type) or hemiplegic migraine headache, or retinal migraine.

  6. Participant was >50 years old at age of first migraine onset.

  7. Participant is taking migraine prophylactic medication where the prescribed daily dose has changed during the 3 months prior to screening (Visit 1) or anticipates any change during the study. Any withdrawal of preventive medications for the treatment of migraine should be completed at least 30 days prior to screening.

    Medical history related

  8. Participant has, in the opinion of the investigator, other confounding pain syndromes, psychiatric conditions such as uncontrolled major depression, history of psychosis, dementia or significant neurological disorders other than migraine [participants who are currently being treated with non-prohibited medication for depression and symptoms are well controlled, in the opinion of the investigator, are eligible to participate in this study].

  9. Participant is at imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicidality Severity Rating Scale (C-SSRS), or of harm to others in the opinion of the investigator. Participants must be excluded if they report suicidal ideation with intent, with or without a plan (i.e., Type 4 or 5 on the C-SSRS) in the past 2 months or suicidal behavior in the past 6 months.

  10. Has a recent history (within the past 3 years of the Screening Visit) or current diagnosis or evidence of endocrine, hematological, immunological, renal, respiratory, neurologic, gastrointestinal, biliary, or genitourinary abnormalities or diseases that, per the investigator's judgement, may jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.

  11. Has a history of malignant neoplasms within the past 5 years prior to screening. Basal and squamous cell skin cancer and any carcinoma in-situ are allowed if they have received treatment and follow-up consistent with local standard of care.

  12. Participant history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Participants with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient ischemic attack (TIA) during the 6 months prior to screening.

  13. Has a history of human immunodeficiency virus disease.

  14. Participant has a history of gastric or small intestinal surgery (including gastric bypass surgery or banding but not including cholecystectomy or appendectomy) or has a disease that causes malabsorption.

    Laboratory, vital sign, and electrocardiogram (ECG) related

  15. Has a positive test result at screening for hepatitis B surface antigen (Ag), hepatitis C virus antibody.

  16. Has a screening estimated Glomerular Filtration Rate (eGFR) estimated with the Modification of Diet in Renal Disease (MDRD) equation of <45 ml/min/1.73 m^2.

  17. Has a screening result for alanine aminotransferase or aspartate aminotransferase (ALT or AST) of >2.0X upper limit of normal (ULN) or total bilirubin >1.5X ULN at the Screening Visit. Note: An isolated bilirubin >1.5X ULN is acceptable if bilirubin is fractionated, and direct bilirubin is within the laboratory normal range.

  18. Has a corrected QT interval to Fridericia's formula (QTcF) >450 milliseconds (msec) for males and >470 msec for females at screening.

  19. Has a mean value for triplicate seated systolic blood pressure >160 mmHg and/or diastolic blood pressure (BP) >95 mmHg measured after at least 5 minutes at rest at the Screening Visit.

    Note: If a participant's BP is exclusionary on the first triplicate assessment at the Screening Visit, they may have 1 repeat triplicate BP assessment at that visit after another rest of at least 10 minutes.

    Medication use and substance abuse related

  20. Has known history of or suspected abuse of alcohol or recreational drugs at screening.

  21. Has use of soft drugs (such as marijuana or any substances containing tetrahydrocannabinol (THC) or cannabidiol (CBD)) within 3 months prior to screening, or hard drugs (such as cocaine, illicit narcotics/opiates) within 6 months prior to screening.

  22. Has a positive drug screen at screening. Note: If benzodiazepines are detected on the drug screen, this is not exclusionary if they are prescribed a benzodiazepine for a therapeutic purpose (e.g. for insomnia) and confirmatory documentation is obtained from the prescribing physician.

  23. Is currently in violation of study requirements for prohibited and permissible concomitant medications (not already specified in other criteria) or is anticipated to violate these requirements during study participation.

  24. Has any use of prescription opiate medications within 14 days of screening or any anticipated/potential use of opiates during study participation.

  25. History of use of ergotamine medications on greater than/equal 10 days per month on a regular basis for greater than/equal 3 months prior to screening.

  26. History of non-narcotic analgesic intake on greater than/equal 15 days per month for greater than/equal 3 months prior to screening.

    Other

  27. Has known or suspected hypersensitivity to trial product(s) or related products.

  28. Has a history of multiple significant and/or any severe allergies (e.g., food, drug, latex allergy) or has had an anaphylactic reaction or significant intolerance to prescription or nonprescription drugs or food.

  29. Has any surgery scheduled for the duration of the trial.

  30. Had major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the Screening Visit; has a screening hemoglobin <11.0 g/dL (males) or <10.0 g/dL (females), or has a known hemoglobinopathy (e.g. sickle cell anemia, hemolytic anemia).

  31. Has previous participation in this trial. Participation is defined as signed informed consent.

  32. Has participated in any clinical trial of an approved or non-approved investigational biological medicinal product (e.g. antibody therapy) within 90 days of screening or has participated in any clinical trial of an approved or non-approved investigational small molecule medicinal product within 30 days or 5 half-lives (whichever is longer) of screening.

  33. Has any other disorder, unwillingness or inability, not covered by any of the other exclusion criteria, which in the investigator's opinion, might jeopardize the participant's safety or compliance with the protocol, or otherwise interfere with interpretation of efficacy and/or safety results.

  34. Is an employee or immediate family member (e.g., spouse, parent, child, sibling) of the Sponsor or study site.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Verdreifachen

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Elismetrep (K-304) Dose Level 1

Participants received a single dose of elismetrep 2 mg

Administered orally

Experimental: Elismetrep (K-304) Dose Level 2

Participants received a single dose of elismetrep 5 mg

Administered orally

Experimental: Elismetrep (K-304) Dose Level 3

Participants received a single dose of elismetrep 10 mg

Administered orally

Experimental: Elismetrep (K-304) Dose Level 4

Participants received a single dose of elismetrep 20 mg

Administered orally

Placebo-Komparator: Placebo

Participants received a single dose of elismetrep-matched placebo

Administered orally

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Pain Freedom
Zeitfenster: 2 hours post-dose

Assessed using the number of evaluable participants that reported no pain at 2 hours post-dose. Pain was measured on a 4-point Likert scale (0 = none, 1 = mild, 2 = moderate, 3 = severe)

2 hours post-dose

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Proportion of Participants Who Experienced 1 or More Treatment-emergent Adverse Events (AEs)
Zeitfenster: up to 7 days after administration of study therapy
up to 7 days after administration of study therapy
Freedom From the Most Bothersome Symptom (MBS) (Nausea, Phonophobia or Photophobia)
Zeitfenster: 2 hours post-dose

Assessed using the number of evaluable participants that reported the absence of their MBS

2 hours post-dose
Pain Relief
Zeitfenster: 2 hours post-dose

Assessed using the number of evaluable participants that reported a pain level of moderate or severe (responses of 2 or 3 on the 4-point Likert scale) at baseline and then reported a pain level of none or mild (response of 0 or 1).

2 hours post-dose
Freedom From Photophobia
Zeitfenster: 2 hours post-dose

Assessed by tabulating the number of participants that reported the absence of photophobia at 2 hours post-dose in the subset of participants that reported the presence of photophobia at baseline.

2 hours post-dose
Freedom From Phonophobia
Zeitfenster: 2 hours post-dose

Assessed by tabulating the number of participants that reported the absence of phonophobia at 2 hours post-dose in the subset of participants that reported the presence of phonophobia at baseline.

2 hours post-dose
Freedom From Nausea
Zeitfenster: 2 hours post-dose

Assessed by tabulating the number of participants that reported the absence of nausea at 2 hours post-dose in the subset of participants that reported the presence of nausea at baseline.

2 hours post-dose
The Probability of Requiring Rescue Medication
Zeitfenster: 24 hours post-dose

Assessed using the number of participants that took rescue medication within 24 hours after administration of study therapy

24 hours post-dose
Sustained Pain Freedom
Zeitfenster: From 2 to 24 hours

Assessed using the number of participants that did not experience any headache pain through the time period of interest

From 2 to 24 hours
Sustained Pain Relief
Zeitfenster: From 2 to 24 hours

Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest.

From 2 to 24 hours
Sustained Pain Freedom
Zeitfenster: From 2 to 48 hours

Assessed using the number of participants that did not experience any headache pain through the time period of interest.

From 2 to 48 hours
Sustained Pain Relief
Zeitfenster: From 2 to 48 hours

Assessed using the number of participants that did not experience any moderate or severe headache pain through the time period of interest.

From 2 to 48 hours
Proportion of Participants Who Experienced 1 or More Treatment-emergent Serious Adverse Events (SAEs)
Zeitfenster: Up to 7 days after administration of study therapy

Serious adverse events were assessed in the Safety Analysis Set.

Up to 7 days after administration of study therapy

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

11. März 2025

Primärer Abschluss (Tatsächlich)

4. August 2025

Studienabschluss (Tatsächlich)

4. August 2025

Studienanmeldedaten

Zuerst eingereicht

21. Februar 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

25. Februar 2025

Zuerst gepostet (Tatsächlich)

26. Februar 2025

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

16. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

30. Oktober 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • K-304 P001

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .